论文部分内容阅读
T细胞淋巴瘤(TCL)是来源于T淋巴细胞的一类恶性淋巴肿瘤,目前尚无统一的最佳治疗方法。虽近年有新的治疗药物,但都只基于少量的病例或小规模的Ⅱ期临床试验。美国国立卫生研究院对于非皮肤型外周TCL的原则为一线治疗方案首选临床试验。且一线巩固方案除低危患者外,应考虑行大剂量化学治疗(化疗)联合造血干细胞移植。另外由于间变性淋巴瘤激酶基因阳性的间变大细胞淋巴瘤预后较好,对处于完全缓解期者无需行干细胞移植。二线治疗方案中,对于耐受大剂量化疗的患者首选临床试验。对于不能耐受大剂量化疗的患者首先考虑参加临床试验,其次使用新药(如阿仑单抗、硼替佐米、地尼白介索、吉西他滨等)及放射治疗,或根据原癌基因或抑癌基因进行治疗。现就其治疗进展作一综述。
T-cell lymphoma (TCL) is a type of malignant lymphatic tumor derived from T lymphocytes. There is no unified best treatment. Although there are new treatments in recent years, they are only based on a small number of cases or small-scale phase II clinical trials. The National Institutes of Health's principle for non-skin-type peripheral TCL is the first-line clinical trial of first-line treatment options. And first-line consolidation program in addition to low-risk patients, should consider the line of high-dose chemotherapy (chemotherapy) combined hematopoietic stem cell transplantation. In addition, as a result of anaplastic lymphoma kinase gene positive mesenchymal lymphoma prognosis is good, in complete remission without the need for stem cell transplantation. In second-line regimens, clinical trials are preferred for patients who tolerate high-dose chemotherapy. For patients who can not tolerate high-dose chemotherapy, they first consider participating in clinical trials, followed by new drugs (such as alemtuzumab, bortezomib, dysentery, gemcitabine, etc.) and radiation therapy, or oncogene or tumor suppressor Gene for treatment. Now on the progress of treatment are reviewed.